– USA, MA – Boston Pharmaceuticals, a clinical-stage biopharmaceutical company, today announced the appointment of Dr. Sophie Kornowski (PharmD) as Chair of its Board of Directors and Acting CEO, effective immediately, succeeding interim Co-CEOs Dr. Joanne Beck and Dr. Craig Basson, who will continue in their respective positions of COO and CMO.
“We are very pleased that Sophie has accepted our invitation to lead Boston Pharmaceuticals into the next phase of its growth trajectory, which includes continued expansion and progress of the pipeline, and the development of a strategy for long-term evolution. Boston Pharmaceuticals, greatly inspired by our legacy in innovative pharma and biotech, is an important investment for B-Flexion and we look forward to Sophie leading the company into its next phase of growth,” said current Board Chairman, Stefan Meister who is also Vice-Chairman of the B-Flexion investment group, which owns the company.
About Dr. Sophie Kornowski
Since 2018, Dr. Sophie Kornowski has been a partner at Gurnet Point Capital, a private investment firm focused on the healthcare sector. In this role, she has worked closely with the Boston Pharmaceuticals team for several years, as a member of the Board of Directors and, at the request of the Board, has recently supported Corporate Development efforts.
Sophie Kornowski commented: “I have worked closely with the Boston Pharmaceuticals team for several years, and it is a great honor to expand my role at this exciting time for the company. Along with the rest of the board and management team, my focus will be on building the company’s successful history of in-licensing differentiated molecules and developing them in a focused and nimble fashion. I am looking forward to leveraging the firm’s strong organizational capability, diverse pipeline, and existing and future financial backing to build sustainable, best-in-class growth biotech that will provide medicines for many patients in need of new options.”
In her position at Gurnet Point Capital, Dr. Kornowski has been a successful investor in several innovative start-ups and high-growth businesses that have products in the clinic or commercialize, diseases such as Attention Deficit Disorder Hyperactivity, Cancer, and Food Allergy.
Before joining Gurnet Point Capital, she was EVP of Roche Partnering and a member of the Extended Corporate Executive Committee of F. Hoffmann-La Roche AG, one of the world’s largest healthcare companies, and a board member of Chugai Pharmaceuticals. In that role, working closely with R&D and Commercial teams at Roche and Genentech, she was responsible for the Partnering and the M&A strategy with Biotechs, Pharma, HealthTech, and Research Institutions worldwide for Roche. Previously, Dr. Kornowski had led the largest affiliate of F. Hoffmann-La Roche outside of the US, based in France for many years. Earlier in her career, she held several leadership commercial roles across geographies in leading innovative pharmaceutical and diagnostic companies in France, Israel, and the US.
Dr. Kornowski holds an MBA from the University of Chicago Booth and a Doctorate in Pharmacy from Paris Descartes University.
About Boston Pharmaceuticals
Boston Pharmaceuticals is a clinical-stage biopharmaceutical company, that leverages an experienced drug development team, to advance a portfolio of differentiated molecules that address important unmet medical needs. The Company partners with innovative biotechnology and pharmaceutical companies to in-license or acquire drug development candidates. It applies rigorous decision-making to advance programs to deliver new differentiated medicines to patients in need of new options. Boston Pharmaceuticals is continuously seeking new opportunities to leverage its model of pipeline externalization for partners, to create a path to value creation, that will benefit all parties.
For more information: https://www.bostonpharmaceuticals.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
